Cogent Biosciences, Inc.: total assets
Total assets for Cogent Biosciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Cogent Biosciences, Inc. financial histories
What this measure means
Resources recognized on the balance sheet. Book assets are not the market value of the business.
Exact concept: us-gaap:Assets. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 937,607,000 | USD | 2026-02-17 | 10-K · 0001193125-26-053334 |
| At date | 2024-12-31 | 327,898,000 | USD | 2026-02-17 | 10-K · 0001193125-26-053334 |
| At date | 2023-12-31 | 313,437,000 | USD | 2025-02-25 | 10-K · 0000950170-25-026115 |
| At date | 2022-12-31 | 300,810,000 | USD | 2024-02-26 | 10-K · 0000950170-24-019770 |
| At date | 2021-12-31 | 232,092,000 | USD | 2023-03-14 | 10-K · 0000950170-23-007729 |
| At date | 2020-12-31 | 250,916,000 | USD | 2022-03-15 | 10-K · 0001564590-22-010238 |
| At date | 2019-12-31 | 49,423,000 | USD | 2021-03-16 | 10-K · 0001564590-21-013325 |
| At date | 2018-12-31 | 85,927,000 | USD | 2020-03-26 | 10-K · 0001564590-20-013188 |
| At date | 2017-12-31 | 49,115,000 | USD | 2019-03-28 | 10-K · 0001193125-19-089299 |
Related financial histories
- Cogent Biosciences, Inc.: total liabilities
- Cogent Biosciences, Inc.: stockholders equity
- Cogent Biosciences, Inc.: cash and cash equivalents
- Cogent Biosciences, Inc.: net income or loss
- Cogent Biosciences, Inc.: operating cash flow
- Cogent Biosciences, Inc.: capital expenditure payments
- Cogent Biosciences, Inc.: financing cash flow
- Cogent Biosciences, Inc.: investing cash flow
- Cogent Biosciences, Inc.: retained earnings or deficit
- Cogent Biosciences, Inc.: basic weighted-average shares
- Cogent Biosciences, Inc.: diluted weighted-average shares
- Cogent Biosciences, Inc.: basic earnings per share
- Cogent Biosciences, Inc.: diluted earnings per share
- Cogent Biosciences, Inc.: net property, plant and equipment
- Cogent Biosciences, Inc.: share-based compensation expense
- Cogent Biosciences, Inc.: operating income or loss
- Cogent Biosciences, Inc.: current assets
- Cogent Biosciences, Inc.: current liabilities
- Cogent Biosciences, Inc.: current accounts payable
- Cogent Biosciences, Inc.: net current accounts receivable
- Cogent Biosciences, Inc.: research and development expense
Inspect the source
- Entity
- Cogent Biosciences, Inc. / CIK 0001622229
- Captured
- 2026-09-21T17:21:46.131Z
- SEC response SHA-256
b9d94be9f80e344ba0abf34d342bf5afaf417f0105914abe7ecc95aac8b475bf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001622229.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))